The company announced that its board has approved the buyback of 3.45 million equity shares representing 12.26% of the total paid-up equity share capital at a price of Rs 670 per share. The buyback price is 2% lower to its Friday’s closing of Rs 683 on BSE.
The buyback will be done on a proportionate basis through the tender offer and will cost Novartis India nearly Rs 231 crore. The promoters also intend to participate in the proposed buyback offer.
As on June 30, 2017, promoters held 73.40% stake in Novartis India while the public held 26.6%.
In past one month, the stock had outperformed the market by surging 17% against 2% rise in the S&P BSE Sensex.
The trading volumes on the counter jumped more than three-fold with 130,000 shares changed hands on BSE against an average 42,000 shares were traded daily in past two weeks.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)